🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.

RecruitingNAAges 30 Years - anyMaleIRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT07357259 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Recent evidence suggests that both standard-time and delayed-time \[⁶⁸Ga\]Ga-PSMA PET acquisitions can reveal clinically relevant findings, and neither phase should be excluded a priori in routine practice. This study evaluates a streamlined dual-phase protocol consisting of: * A standard whole-body PET/CT acquisition performed 60 minutes after radiotracer administration. * A delayed pelvic PET-only acquisition performed 90 minutes post-injection, reconstructed using the attenuation-correction CT (CT/AC) obtained from the initial whole-body scan. Because the prostate gland and pelvic lymph nodes exhibit minimal physiological mobility, accurate PET-CT anatomical correspondence can be maintained through careful patient repositioning, without repeating the CT scan. The main advantage of this protocol is a reduction in patient radiation exposure, as the delayed phase does not require a se

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Newly diagnosed prostate cancer undergoing staging, or * Biochemical recurrence following prior radical-intent therapy (surgery and/or radiotherapy), or * High-risk prostate cancer, defined as Gleason Score ≥ 8 or PSA ≥ 20 ng/mL. * Written informed consent and authorization for personal data processing. Exclusion Criteria: * Genitourinary comorbidities that could interfere with imaging or interpretation. * Intermediate- or low-risk prostate cancer. * Delayed acquisition performed on a PET/CT scanner different from the standard acquisition. * Additional PET/CT required due to artifacts compromising diagnostic quality (e.g., urinary retention, excessive motion). * Patients previously enrolled who require repeat PET/CT as a new visit. * Inability to provide informed consent or impaired decision-making capacity. * Known hypersensitivity to the radiopharmaceutical or its components. * Contraindications to PET/CT (e.g., severe claustrophobia, morbid obesity, inability to cooperate).
💊

What it tests

  • Intervention Group
📍

Where

1 site
IRCCS - Policlinico Universitario di Sant'Orsola
Bologna, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy